Free Trial

Insmed (INSM) Competitors

Insmed logo
$97.12 +0.98 (+1.02%)
As of 12:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

INSM vs. REGN, ALNY, ARGX, BNTX, RPRX, BIIB, ILMN, GMAB, INCY, and EXEL

Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), argenex (ARGX), BioNTech (BNTX), Royalty Pharma (RPRX), Biogen (BIIB), Illumina (ILMN), Genmab A/S (GMAB), Incyte (INCY), and Exelixis (EXEL). These companies are all part of the "med - biomed/gene" industry.

Insmed vs. Its Competitors

Insmed (NASDAQ:INSM) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Insmed currently has a consensus target price of $108.07, suggesting a potential upside of 11.27%. Regeneron Pharmaceuticals has a consensus target price of $813.57, suggesting a potential upside of 48.86%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Insmed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
0 Sell rating(s)
0 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
3.00
Regeneron Pharmaceuticals
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80

Insmed has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500.

In the previous week, Regeneron Pharmaceuticals had 25 more articles in the media than Insmed. MarketBeat recorded 33 mentions for Regeneron Pharmaceuticals and 8 mentions for Insmed. Insmed's average media sentiment score of 1.13 beat Regeneron Pharmaceuticals' score of 0.95 indicating that Insmed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Regeneron Pharmaceuticals
16 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive

Regeneron Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$363.71M50.66-$913.77M-$5.95-16.32
Regeneron Pharmaceuticals$14.20B4.15$4.41B$39.2813.91

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 3.0% of Insmed shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has a net margin of 31.94% compared to Insmed's net margin of -265.93%. Regeneron Pharmaceuticals' return on equity of 15.27% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed-265.93% -446.98% -52.70%
Regeneron Pharmaceuticals 31.94%15.27%11.93%

Summary

Regeneron Pharmaceuticals beats Insmed on 12 of the 17 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INSM vs. The Competition

MetricInsmedMED IndustryMedical SectorNASDAQ Exchange
Market Cap$18.42B$2.91B$5.53B$8.98B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-16.3220.8927.0720.16
Price / Sales50.66289.54430.62124.91
Price / CashN/A41.1936.8257.86
Price / Book60.707.728.075.57
Net Income-$913.77M-$54.95M$3.17B$248.52M
7 Day Performance-1.14%5.01%3.91%5.05%
1 Month Performance37.41%4.38%3.63%6.98%
1 Year Performance38.21%6.59%34.00%21.36%

Insmed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INSM
Insmed
4.5542 of 5 stars
$97.12
+1.0%
$108.07
+11.3%
+37.2%$18.42B$363.71M-16.321,271Positive News
Analyst Forecast
REGN
Regeneron Pharmaceuticals
4.938 of 5 stars
$525.00
+0.8%
$813.57
+55.0%
-47.9%$56.68B$14.20B13.3711,900Analyst Revision
ALNY
Alnylam Pharmaceuticals
4.1206 of 5 stars
$326.09
+1.0%
$340.00
+4.3%
+24.5%$42.52B$2.35B-156.022,000Positive News
Analyst Forecast
ARGX
argenex
4.3905 of 5 stars
$551.22
-1.6%
$729.93
+32.4%
+23.4%$33.66B$2.58B34.00650Analyst Upgrade
High Trading Volume
BNTX
BioNTech
1.442 of 5 stars
$106.47
-0.2%
$137.86
+29.5%
+38.7%$25.59B$2.98B-31.313,080
RPRX
Royalty Pharma
4.8861 of 5 stars
$36.03
+0.4%
$47.33
+31.4%
+38.1%$20.26B$2.26B19.4880Positive News
BIIB
Biogen
4.9572 of 5 stars
$125.59
-0.4%
$188.48
+50.1%
-41.0%$18.40B$9.68B12.407,605
ILMN
Illumina
4.8669 of 5 stars
$95.41
+0.7%
$127.39
+33.5%
-7.9%$15.10B$4.37B-15.729,030Positive News
Analyst Forecast
Gap Down
GMAB
Genmab A/S
4.0127 of 5 stars
$20.66
+0.8%
$37.60
+82.0%
-16.6%$13.25B$3.12B11.742,682News Coverage
Analyst Forecast
INCY
Incyte
4.7656 of 5 stars
$68.10
-0.4%
$74.53
+9.4%
+16.3%$13.18B$4.24B212.822,617Insider Trade
EXEL
Exelixis
4.7074 of 5 stars
$44.08
+0.9%
$43.56
-1.2%
+97.0%$12.02B$2.17B20.041,147Analyst Forecast
Options Volume

Related Companies and Tools


This page (NASDAQ:INSM) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners